The U.S. Food and Drug Administration (FDA) is recommending federal scheduling for highly concentrated kratom products containing synthetic or enhanced 7-hydroxymitragynine (7-OH), a powerful opioid-like compound, following regulatory actions in states like Mississippi. The FDA stresses its proposal does not target natural kratom leaf products, which contain only low levels of 7-OH, but rather focuses on lab-made or fortified products that may contain up to 98% 7-OH.
Mississippi’s new law, HB 1077, bans kratom products with more than 1% 7-OH and restricts sales to those age 21 and over. Advocates argue natural kratom helps people avoid stronger opioids, while critics cite the heightened risk of synthetic products. The debate continues, with more details at the original Northside Sun article and in the FDA’s official press release.